ClinicalTrials.gg
RecruitingNCT04095195IRFARPCUpdated Jan 13, 2023

Registry of Subjects at Risk of Pancreatic Cancer

An observational study in Familial Pancreatic Cancer, BRCA1 Mutation and BRCA2 Mutation, sponsored by Associazione Italiana per lo Studio del Pancreas. Recruiting at 4 sites in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-01-13.

Sponsored by Associazione Italiana per lo Studio del Pancreas · Observational

How we know

From the registry’s dates

  • Started Aug 2019; still recruiting 7 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in Italy — 9 open to participants now, 9 under way, none of them phase 3. Colorectal Neoplasms, Hereditary Nonpolyposis · Italy.

Started
2019
the only one that year
Observational
7 of 10
6 open now
Registered
1st of 10
by date
Lead sponsor
1 of 10
Associazione Italiana per lo Studio del Pancreas

Among the 10 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in Italy, this one is the only one that started in 2019, is one of 7 observational ones, and was the 1st registered.

Colorectal Neoplasms, Hereditary Nonpolyposis

147 studies on the registry are indexed under Colorectal Neoplasms, Hereditary Nonpolyposis; 61 are open to participants now.

Browse Colorectal Neoplasms, Hereditary Nonpolyposis studies →

Open to participants now

9 of the 10 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in Italy are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 43 Colorectal Neoplasms, Hereditary Nonpolyposis studies recruiting now, 32 (74%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in Italy, or all of them as a file.
02

Study summary

IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.

Read the detailed description

Pancreatic cancer is a devastating disease with a dismal prognosis. One of the ways to improve survival might be early detection.

Within years, many predisposing diseases or genetic conditions have been identified, thus screening/surveillance have been established worldwide.

A registry of subjects at risk of pancreatic cancer will has been built up to investigate the possibility of diagnosis pancreatic cancer, or one if its predisposing lesions.

Inclusion criteria will be adopted as "enrollment criteria". According to this, individuals > 18 years old will be enrolled; their familiar history and/or genetic predisposition will be collected, as well as current or previous medical records/medications data. Thereafter, according to specific age-based criteria, those individuals initially enrolled will be will be considered for a "surveillance protocol" ("interventional follow-up criteria") and they will be submitted to Cholangio-Wirsung Magnetic Resonance or Pancreatic Endoultrasonography according to the pancreatologist's prescription at each participating center.

Individuals suffering from the following conditions will be enrolled:

familial pancreatic cancer; Peutz-Jeghers syndrome; a known BRCA-2, BRCA-1, PALB2, or p16 mutation with at least one first- or second-degree relative suffering from pancreatic cancer; hereditary pancreatitis; FAMMM syndrome; Lynch syndrome with at least one first- or second-degree relative suffering from pancreatic cancer.

03

Conditions studied

  • Familial Pancreatic Cancer
  • BRCA1 Mutation
  • BRCA2 Mutation
  • Lynch Syndrome
  • FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome
  • Hereditary Pancreatitis
  • Peutz-Jeghers Syndrome

Keywords

  • Familial Pancreatic Cancer
  • BRCA Mutation
  • Lynch Syndrome
  • Screening pancreatic cancer
  • Surveillance pancreatic cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Subjects at high-risk of pancreatic cancer will be enrolled and a surveillance examination will be performed according to inclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • individuals with at least two relatives suffering from pancreatic cancer, with at least 1 first-degree and until the third-degree
  • subjects with known genetic mutation of BRCA2, BRCA1, p16, PALB2 with at least 1 first- or 2nd-degree relative suffering from pancreatic cancer
  • subjects suffering from FAMMM Syndrome
  • subjects suffering from Peutz-Jeghers Syndrome
  • subjects suffering from PRSS-1- or CFTR- or SPINK-1- related pancreatitis
  • subjects suffering from Lynch syndrome with at least 1 first- or 2nd-degree relative suffering from pancreatic cancer

Inclusion criteria to join the "radiologic follow-up":

  • 45 years or 10 years younger than the youngest index case of pancreatic cancer in the family for familial cases
  • 40 years or 5 years younger than the youngest index case of pancreatic cancer for subjects suffering from hereditary/genetic pancreatitis, Lynch syndrome, or carrying a known BRCA 1/2, PALB2, p16 genetic mutation with familiarity for pancreatic cancer
  • 30 years for subjects suffering from FAMMM, Peutz-Jeghers syndrome

Exclusion criteria

Exclusion Criteria:

  • pregnancy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Familial pancreatic cancer relatives

    Radiation: MRCP · Procedure: Endoultrasonography

  • Peutz-Jeghers syndrome

    Radiation: MRCP · Procedure: Endoultrasonography

  • BRCA 1/2, PALB2, p16 mutations with familiarity for PC

    Known genetic mutation and at least 1 1st- or 2nd-degree relative suffering from PC

    Radiation: MRCP · Procedure: Endoultrasonography

  • Lynch syndrome with familiarity for pancreatic cancer

    Radiation: MRCP · Procedure: Endoultrasonography

  • FAMMM syndrome

    Radiation: MRCP · Procedure: Endoultrasonography

  • Hereditary and genetic pancreatitis

    Radiation: MRCP · Procedure: Endoultrasonography

Interventions

  • RadiationMRCP

    Subjects fulfilling the "radiological follow-up criteria" will be submitted to MRCP or EUS according to the pancreatologist's prescription

  • ProcedureEndoultrasonography

    Subjects fulfilling the "radiological follow-up criteria" will be submitted to MRCP or EUS according to the pancreatologist's prescription

06

What researchers measure

Primary outcomes

  1. This clinical study will assess the diagnostic yield of a clinical surveillance program for pancreatic neoplasia or predisposing conditions (PanIN, IPMNs) in high risk individuals

    Number of malignant and pre-malignant lesions diagnosed over time

    Time frame: 25 years

Secondary outcomes

  1. This study will investigate possible risk factors for the incidence or the progression of for pancreatic neoplasia or predisposing conditions (PanIN, IPMNs) in high risk individuals

    Identification of risk factors for malignant or pre-malignant lesions diagnosis

    Time frame: 25 years

07

Study locations

4 of 4 sites recruiting
  • Istituto Clinico Humanitas
    Rozzano, Milan, Italy
    Recruiting
    • Silvia Carrara, MD · Contactsilvia.carrara@humanitas.it
    • Alessandro Zerbi, MD · Principal investigator
    • Luigi Laghi, MD, PhD · Principal investigator
    • Laura Poliani, MD · Sub investigator
    • Valentina Giatti · Sub investigator
  • Ospedale Pederzoli
    Peschiera Del Garda, Verona, Italy
    Recruiting
    • Giovanni Butturini, MD · Contact
    • Alessandro Giardino, MD, PhD · Sub investigator
    • Isabella Frigerio, MD, PhD · Sub investigator
  • San Raffele Vita Salute University Hospital
    Milano, Italy
    Recruiting
    • Massimo Falconi, MD · Contactmassimo.falconi@hsr.it
    • Gabriele Capurso, MD, PhD · Principal investigator
    • Silvia Smaniotto · Sub investigator
  • Chirurgia Generale e del Pancreas
    Verona, 37134, Italy
    Recruiting
    • Salvatore Paiella, MD, PhD · Contactsalvatore.paiella@univr.it · 00390458126009
    • Erica Secchettin, PharmD · Contacterica.secchettin@univr.it · 00390458126254
    • Salvatore Paiella, MD, PhD · Principal investigator
    • Giuseppe Malleo, MD, PhD · Principal investigator
    • Claudio Bassi, MD · Principal investigator
    • Roberto Salvia, MD, PhD · Principal investigator
    • Erica Secchettin, PharmD · Sub investigator
    • Veronica Marinelli, PhD · Sub investigator
08

References and documents

Publications

  • Paiella S, Capurso G, Cavestro GM, Butturini G, Pezzilli R, Salvia R, Signoretti M, Crippa S, Carrara S, Frigerio I, Bassi C, Falconi M, Iannicelli E, Giardino A, Mannucci A, Laghi A, Laghi L, Frulloni L, Zerbi A. Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Registry. Am J Gastroenterol. 2019 Apr;114(4):665-670. doi: 10.1038/s41395-018-0414-z. PubMed 30538291 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2019 (actual). Primary completion is estimated for Aug 2044, 300 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2019
First posted
Sep 19, 2019
StartActual
Aug 20, 2019
Primary completionEst.
Aug 20, 2044
CompletionEst.
Sep 20, 2045
Last update
Jan 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04095195
Lead sponsor
Associazione Italiana per lo Studio del Pancreas
Responsible party
Sponsor
First posted
Sep 19, 2019
Start date
Aug 20, 2019
Primary completion
Aug 20, 2044 (estimated)
Completion
Sep 20, 2045 (estimated)
Last update
Jan 13, 2023

Study contacts

Salvatore Paiella, MD, PhD
Contact
salvatore.paiella@univr.it
00390458126009
Silvia Carrara, MD
Contact
silvia.carrara@humanitas.it
+ 39 02 82247288

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion